News

October 18, 2017

FDA Grants Priority Review to Application for Opdivo as Treatment for Resected Advanced Melanoma

News

The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb’s (BMS) supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) as a treatment for resected high-risk advanced melanoma. The agency also ... Read more

October 17, 2017October 17, 2017

SCLC Patients with High Tumor Mutation Burden Show Promising Responses to Opdivo Alone or with Yervoy

News

Bristol-Myers Squibb’s Opdivo (nivolumab), with or without Yervoy (ipilimumab), showed promising overall survival rates in previously treated patients with small cell lung cancer (SCLC) who had high tumor mutation burden ... Read more

October 16, 2017

Large-scale Collaborative Effort Aims to Increase Understanding of Cancer Therapy Combinations

News

In an unprecedented collaborative effort, Stand Up To Cancer (SU2C) has launched 10 clinical trials through its therapy development initiative SU2C Catalyst — projects that will involve researchers from more than ... Read more

October 13, 2017October 13, 2017

Presage Biosciences Awarded Grant to Develop CIVO Microdosing Platform Used Inside Tumors

News

The Mark Foundation for Cancer Research, a newly formed nonprofit organization, announced that its first grant will be awarded to Presage Biosciences to advance CIVO, a drug-development platform that injects therapies and ... Read more

October 12, 2017October 12, 2017

Imlygic-Yervoy Combo Twice as Effective as Yervoy in Fighting Melanoma, Study Finds

News

Amgen’s virus therapy against metastatic malignant melanoma, Imlygic, appears to boost the effects of Yervoy (ipilimumab), according to the results of a Phase 2 clinical trial published in the Journal ... Read more

October 11, 2017October 11, 2017

Microsatellite Stable Colorectal Cancer Dosing Begins in Phase 2 Trial of Combo Therapy

News

Microsatellite stable colorectal cancer (MSS CRC) patients have begun receiving treatment in a Phase 2 clinical trial evaluating eFT508 in combination with Bavencio (avelumab), eFFECTOR Therapeutics announced. In collaboration with Pfizer and ... Read more

October 10, 2017October 10, 2017

EMA to Review Marketing Application for Imfinzi as NSCLC Treatment

News

The European Medicines Agency (EMA) has accepted for review a marketing authorization application to approve Imfinzi (durvalumab) to treat patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has ... Read more

October 9, 2017

SELLAS and Merck Plan Phase 1/2 Trial of Galinpepimut-S and Keytruda in Five Cancers

News

SELLAS Life Sciences and Merck will collaborate on a Phase 1/2 clinical trial assessing the galinpepimut-S vaccine in combination with Keytruda (pembrolizumab) as a treatment for a number of cancers. Galinpepimut-S is a peptide ... Read more

October 6, 2017October 6, 2017

FDA Approves Quicker L-DOS47 Dose Escalation in Phase 1 Lung Cancer Trial

News

The U.S. Food and Drug Administration (FDA) has approved the acceleration of dose escalation in a Phase 1 clinical trial in the United States to evaluate Helix BioPharma‘s immuno-conjugate L-DOS47 for the treatment of ... Read more

October 5, 2017October 5, 2017

MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors

News

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say they’ll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers. The ... Read more